| Literature DB >> 33818894 |
Colette J Shen1, Stephanie M Perkins2, Julie A Bradley3, Anita Mahajan4, Karen J Marcus5.
Abstract
The clinical outcomes for infants with malignant tumors are often worse than older children due to a combination of more biologically aggressive disease in some cases, and increased toxicity-or deintensification of therapies due to concern for toxicity-in others. Especially in infants and very young children, finding the appropriate balance between maximizing treatment efficacy while minimizing toxicity-in particular late side effects-is crucial. We review here the management of malignant tumors in infants and very young children, focusing on central nervous system (CNS) malignancies and rhabdomyosarcoma.Entities:
Keywords: brain tumors; cancer; chemotherapy; infants; late effects; radiation therapy; rhabdomyosarcoma; surgery
Year: 2021 PMID: 33818894 DOI: 10.1002/pbc.28700
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167